Wall Street analyst estimates for BeyondSpring Inc. (BYSI): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer.
Valuation Ratios
| Price / Book | -0.82 |
| EV / EBITDA | -2.91 |
| Dividend Yield | 0.00% |
Price
| Price | $0.71 |
| Market Cap | $29M |
| Exchange | NASDAQ |
| Country | US |
Explore sector: Healthcare · Biotechnology
More sections of BYSI: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks